ID: VIEW4619A06E01C00
Name: Dual Use

View: Final Page (submitted)

Final Page of IBC Application

ID: VIEW44ACF8C728000
Name: Final Page (submitted)

View: EHS - Add Principal Investigator

Add Principal Investigator

1. * Select the PI - the person conducting the research. All individuals categorized as HRPO or IACUC researchers will be shown when you click 'Select', you can search for the specific person you need by last name:
   Melissa PI
2. Degree or Certification (if applicable):
3. What procedures will this person be performing?
4. Qualifications and training as it specifically relates to the procedures to be performed:
5. If the person is not trained, please indicate how he/she will be trained:

View: EHS - Add Coordinator

Add Research Coordinator

1. * **Select the Coordinator**- the coordinator is the primary point of contact, the person who fills out the forms, communicates with review authorities, responds to requests for changes/clarifications, etc. The coordinator has full edit rights for the online forms (PI and Coordinator can be same person). All individuals categorized as HRPO or IACUC researchers will be shown when you click 'Select', you can search for the specific person you need by last name:
   Melissa PI
2. Degree or Certification (if applicable):
3. What procedures will this person be performing?:
4. Qualifications and training as it specifically relates to the procedures to be performed:
5. If the person is not trained, please indicate how he/she will be trained:

View: IBC Lab Locations editor

Location Where Work Will Be Performed

1. * Building Name (only enter one building):
   01/05/12 test
2. * Room Number (only enter one room number):
   01/05/12 test
3. * Types of procedures to be performed in this room:
   01/05/12 test

View: Recombinant DNA Animal and In Vitro

Host/Vector Systems (Animal and *In Vitro*)

1. * Nature of the Inserted DNA Sequences (Gene of Interest):
   Description of inserted sequences.
2. * Organism From Which the DNA Was Derived:
   Organism
3. * Host:
   Host
   3.1 - Host NIH Risk Group Classification: Risk Group 2
4. * Vector. Please provide the complete name, not just the acronym:
   Complete vector description

4.1 - Vector NIH Risk Group Classification: Risk Group 2

4.2 - Does Vector contain greater than 2/3 of Virus Genome? (•) Yes ( ) No

4.3 - Is Vector replication defective? Answer "Yes" for plasmid vectors. (•) Yes ( ) No

4.3.1 - If Yes, provide evidence or documentation to substantiate replication incompetence and method to ensure that replication-competent virus is not generated. Enter "n/a" for plasmid vectors.
Provide information to support claim of replication incompetennce.

5 * Use of helper virus or packaging cells? (•) Yes ( ) No

5.1 If yes, and if packaging cells are used with murine retroviral vectors, does this broaden the host range of the virus (e.g. from ecotropic to amphotropic)? Please discuss (include packaging cell line, tropism, and added risk of a broadened host range, if applicable):
This pertains to murine retroviral vectors.

6 * Protein Expression? (•) Yes ( ) No

6.1 - If Yes, enter Expressed Protein Name:

7 * Transfer of Drug Resistance Gene? (•) Yes ( ) No

7.1 - If Yes, is this drug resistance trait acquired naturally by the microorganism? (•) Yes ( ) No

7.1.1 - Will the acquisition of the trait compromise the use of the drug to control disease agents in humans, veterinary medicine, or agriculture? (•) Yes ( ) No

7.1.1.1 - Name the antibiotic resistance gene and support your answer to 7.1.1 in sufficient detail for IBC review:
Supplemental information.

8 * Does work involve cloning of toxin molecules with an LD50 of < 100 NG/KG of body weight? (•) Yes ( ) No

9 * Is there production of Transgenic Animals? (•) Yes ( ) No

9.1 If Yes, what precautions are taken to prevent release of animals to the wild?
Supplemental information.

10 * Is there use of recombinant organisms in animals? (•) Yes ( ) No

10.1 If Yes, Is there the possibility of horizontal transmission? ( ) Yes ( ) No

10.1.1 If Yes to 10.1, what precautions are taken to prevent release of animals to the wild?
Supplemental information.

11 * Does work use an E. coli K12 Host vector system or other non-pathogenic strain? (•) Yes ( ) No

11.1 - If Yes, identify genus, species and strain:

12 * Is the work in cell or tissue culture? (•) Yes ( ) No

12.1 If Yes, do the recombinant DNA molecules contain > 1/2 of any eukaryotic viral genome?: (•) Yes ( ) No

12.2 If Yes to 12, identify cell lines:
Supplemental information.

13 Having answered the previous questions, you have sufficient information to identify the relevant section and subsections and, if applicable, an appendix in the NIH Guidelines for Recombinant DNA Research:

* 13.1 - Section III: A

* 13.2 - Subsection: 1

13.3 - Subsection: a

13.4 - Relevant NIH appendix: C

13.5 - If you have categorized your work as being exempt from the Guidelines (Section III: F), please provide specific information as to how your work meets the criteria for exemption:
Supplemental information rquired if the NIH categorization is III. F.